Suchergebnisse - "Oluwole, Olalekan O"

PubPharm (16)

1

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

enthalten in: Blood | 2024

von Neelapu, S. | Chavez, J. | Sehgal, A. | +23

CommentIn: Blood. 2024 Feb 8;143(6):475-476. - PMID 38329775

2

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

enthalten in: Blood advances | 2023

von Scordo, M. | Flynn, J. | Gonen, M. | +19

CommentIn: Blood Adv. 2024 Feb 13;8(3):797-798. - PMID 38191740

3

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome

enthalten in: Blood advances | 2023

von Bhaskar, S. | Patel, V. | Porter, D. | +12

4

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

enthalten in: Blood | 2023

von Neelapu, S. | Jacobson, C. | Ghobadi, A. | +27

CommentIn: Blood. 2023 May 11;141(19):2285-2286. - PMID 37166931

5

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma

enthalten in: Haematologica | 2023

von Zurko, J. | Ramdial, J. | Shadman, M. | +39

6

Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

enthalten in: Journal of hematology & oncology | 2022

von Shah, B. | Ghobadi, A. | Oluwole, O. | +27

7

Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas

enthalten in: Transplantation and cellular therapy | 2022

von Riedell, P. | Hwang, W. | Nastoupil, L. | +15

CommentIn: Transplant Cell Ther. 2022 Oct;28(10):621-622. - PMID 36202524

8

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma : the phase 2 ZUMA-12 trial

enthalten in: Nature medicine | 2022

von Neelapu, S. | Dickinson, M. | Munoz, J. | +14

CommentIn: Nat Rev Clin Oncol. 2022 May;19(5):283. - PMID 35361894

9

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

enthalten in: The New England journal of medicine | 2022

von Locke, F. | Miklos, D. | Jacobson, C. | +129

CommentIn: N Engl J Med. 2022 Feb 17;386(7):692-696. - PMID 34904797

10

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5) : a single-arm, multicentre, phase 2 trial

enthalten in: The Lancet. Oncology | 2022

von Jacobson, C. | Chavez, J. | Sehgal, A. | +20

CommentIn: Lancet Oncol. 2022 Jan;23(1):6-8. - PMID 34895488